Retatrutide vs
Semaglutide vs
Tirzepatide
These three peptides differ chiefly in which incretin receptors they engage: semaglutide is a single GLP-1 agonist, tirzepatide a dual GIP/GLP-1 agonist, and retatrutide a triple GLP-1/GIP/glucagon agonist. Crucially, semaglutide and tirzepatide are licensed medicines, whereas retatrutide is an unlicensed investigational compound supplied strictly for laboratory research use. This compares their molecular pharmacology only — it makes no claims about effects in humans and is not medical advice.
Three compounds, three receptor profiles
Retatrutide, semaglutide and tirzepatide all belong to the broad family of incretin-based peptides — molecules studied in relation to the receptors that regulate glucose handling and energy metabolism. What distinguishes them, in pharmacological terms, is simply how many and which of these receptors each one engages.
This article compares that molecular pharmacology. It does not compare clinical outcomes, and it makes no claim about what any of these compounds do in a human being. Retatrutide is supplied by Omni Peptides strictly as a reference material for laboratory research.
The receptor differences
| Compound | Receptor targets | Regulatory status |
|---|---|---|
| Semaglutide | GLP-1 receptor (single agonist) | Licensed medicine (prescription only) |
| Tirzepatide | GIP + GLP-1 receptors (dual agonist) | Licensed medicine (prescription only) |
| Retatrutide | GLP-1 + GIP + glucagon receptors (triple agonist) | Unlicensed — investigational; research use only |
In short: semaglutide acts at one incretin receptor, tirzepatide at two, and retatrutide at three (adding the glucagon receptor). This receptor count is a factual description of each molecule's binding profile, studied in the pharmacology literature. It is not a statement that engaging more receptors produces any particular effect, benefit or outcome — no such claim is made here.
The regulatory difference matters most
The most important distinction is not pharmacological but regulatory. Semaglutide and tirzepatide are licensed medicines — approved by the MHRA and other regulators, and available only on prescription under medical supervision. Retatrutide is not. It holds no marketing authorisation anywhere, has not been evaluated as safe or effective for use in humans, and is an investigational compound.
Because of that, retatrutide is supplied by Omni Peptides — and should only ever be handled — as a research-grade reference material for laboratory research. It is not a weight-loss product, not a medicine, and not a substitute for a prescribed treatment. Anyone considering a licensed medicine should speak to a qualified healthcare professional. See how UK law treats research peptides for the framework.
Where retatrutide sits in research
Within the scientific literature, retatrutide is of interest precisely because of its triple-receptor profile — it lets researchers study simultaneous engagement of three incretin-related receptors with a single molecule, versus the one or two engaged by earlier compounds. That is the research context in which it appears. Its full profile is set out in our retatrutide research overview, and the batch-tested product is listed on the retatrutide product page.
Frequently Asked Questions
The main difference is which incretin receptors each engages. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist; retatrutide is a triple GLP-1/GIP/glucagon agonist. Semaglutide and tirzepatide are licensed medicines; retatrutide is an unlicensed investigational compound supplied for laboratory research use only.
No. They are different molecules with different receptor profiles, and their regulatory status differs. Semaglutide and tirzepatide are licensed prescription medicines. Retatrutide holds no marketing authorisation, is investigational, and is supplied strictly as a reference material for laboratory research — not a medicine or a substitute for one.
No. Retatrutide has no marketing authorisation from the MHRA or any other regulator and has not been evaluated as safe or effective for any use in humans. It is supplied strictly as a research-grade reference material for laboratory use only.